查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2020213

免疫球蛋白市場規模、佔有率、成長及全球產業分析：按類型和應用、區域的洞察，2026-2034年的預測

Immunoglobulin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 160 Pages | 商品交期: 請詢問到貨日

價格

免疫球蛋白市場成長要素

全球免疫球蛋白市場在2025年達到221.5億美元，預計2026年成長至244.4億美元，並在2034年達到436.8億美元，預測期內年複合成長率（CAGR）為7.53%。北美地區在2025年佔據市場主導地位，市場佔有率達49.39%。這主要得益於免疫不全症盛行率的上升、完善的醫療保健基礎設施以及創新產品的上市。

人類血漿來源的免疫球蛋白是治療方法免疫力缺乏疾病、自體免疫疾病和其他慢性免疫介導疾病的重要手段。除了作為第一線療法的應用日益廣泛外，CSL (Australia)、Takeda Pharmaceutical Company Limited (Japan)、Grifols、S.A. (Spain)、Octapharma AG (Switzerland) 等主要企業持續加強研發投入，也是推動市場擴張的主要動力。監管機構的支持和新型免疫球蛋白產品的快速核准進一步鞏固了市場的成長動力。

市場趨勢

全球一個顯著的趨勢是皮下注射（SCIG）的普及。與靜脈注射（IVIG）相比，SCIG具有許多優勢，包括給藥方便、安全性更高，以及患者可在家中自行注射。這一趨勢有助於提高患者依從性並促進更廣泛的應用。例如，2023年6月，Grifols, S.A.在西班牙推出了濃度為20%的SCIG製劑XEMBIFY，目的是提高患者可及性並促進市場成長。

市場促進因素

對原發性免疫力缺乏（PI）、慢性脫髓鞘多發性神經炎（CIDP）、Guillain-Barré二氏症候群和多灶性運動神經病變（MMN）等免疫不全症治療的需求不斷成長，推動了免疫球蛋白市場的發展。隨著這些疾病盛行率的上升，患者人數也隨之增加，進而擴大了免疫球蛋白療法的需求。根據U.S. Pharmacist誌2025年2月的報告，大約1-2%的美國人口將患有原發性免疫力缺乏症（PIDD）。

市場限制因素

嚴格的政府監管是限制阻礙因素。免疫球蛋白源自血漿，必須符合嚴格的安全性、有效性和品質標準。美國食品藥物管理局（FDA）等監管機構依據公共衛生服務法案（PHS法案）和聯邦食品、藥品和化妝品法案（FD&C法案）對血漿的採集、加工和分銷進行監管。這些要求可能會限制市場快速擴張並增加生產成本。

市場機會

擴大生產能力蘊藏著巨大的成長機會。由於血漿供應和生產限制，供應鏈常常面臨挑戰。為了滿足不斷成長的需求，各公司正投資於高通量純化系統、擴大分餾生產線並改進包裝。2025年2月，OctaPharma AG擴大了位於維也納的生產設施，以提高人類血漿衍生藥物的產量。

市場挑戰

免疫球蛋白療法的高成本是一項重大挑戰。靜脈注射免疫球蛋白（IVIG）和皮下注射免疫球蛋白（SCIG）療法價格昂貴，導致病人自付費用高昂，且健保償付政策不盡相同。供不應求也加劇了價格上漲，限制了其普及應用。例如，挪威一項2024年針對重症肌無力患者的研究表明，接受IVIG治療的患者在第一年的直接醫療費用是未接受治療患者的2.3倍。

市場區隔

依產品類型：

  • 由於靜脈注射免疫球蛋白（IVIG）在醫院中的應用以及其在治療嚴重神經免疫疾病方面的快速療效，IVIG 在市場上佔據主導地位。
  • 受自我給藥的便利性和患者偏好的推動，SCIG預計將以11.18%的年複合成長率成長。

依劑型：

  • 到2025年，液體免疫球蛋白有望佔據市場主導地位，因為它提供即用型配方，可降低污染風險和製備時間。
  • 預計在預測期內，冷凍乾燥製劑的年複合成長率將達到 2.97%。

依最終用戶分類：

  • 由於醫院擁有完善的基礎設施、病患監測和償付機制，因此佔據了最大的佔有率。
  • 居家醫療預計將以 9.18%的年複合成長率成長，這反映了 SCIG 療法的日益普及。

區域展望

北美引領市場，2025年市場規模達114.6億美元，預計2026年將達124.7億美元。光是美國市場預計到2026年將達到111.9億美元。

在政府援助和基礎建設的支持下，歐洲市場在2025年達到36.3億美元，預計在2026年達到39.1億美元。德國和英國市場預計在2026年將分別達到12.4億美元和10.4億美元。

亞太地區2025年的經濟規模達到33.8億美元，預計2026年將達到37.1億美元，其中日本和中國分別以14.1億美元和21.2億美元主導。印度預計2026年的經濟規模將達到6.8億美元。

拉丁美洲和中東及非洲市場將實現溫和成長，到2026年，市場規模預計將分別達到 4.5億美元和 1.8億美元。僅海灣合作理事會地區預計將達到 3億美元。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 主要企業管道分析
  • 產業重大發展動態（合併、收購等）
  • 新產品發布：依主要企業分類
  • 主要國家/地區法規及還款狀況概述
  • 主要國家/地區主要疾病的流行情況

第5章 2021-2034年全球免疫球蛋白市場分析、洞察與預測

  • 市場分析、洞察與預測：依產品類型分類
    • 靜脈注射免疫球蛋白（IVIG）
      • 原發性免疫力缺乏
      • 次發性免疫力缺乏
      • 慢性脫髓鞘多發性神經炎
      • Guillain-Barré二氏症候群
      • 免疫性血小板缺乏紫斑症
      • 多灶性運動神經病變
      • 其他
    • 皮下注射免疫球蛋白（SCIG）
      • 原發性免疫力缺乏
      • 次發性免疫力缺乏
      • 慢性脫髓鞘多發性神經炎
      • 其他
  • 市場分析、洞察與預測：依形式
    • 液體
    • 冷凍乾燥
  • 市場分析、洞察與預測：依最終用戶分類
    • 醫院
    • 診所
    • 居家照護
  • 分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美免疫球蛋白市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 歐洲免疫球蛋白市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章 亞太地區免疫球蛋白市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章 拉丁美洲免疫球蛋白市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章 中東和非洲免疫球蛋白市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • CSL
    • Takeda Pharmaceutical Company Limited
    • Grifols, SA
    • Kedrion SpA
    • Octapharma AG
    • ADMA Biologics, Inc.
    • Taibang Biologic Group（China Biologic Products Holdings, Inc.）
    • LFB Group
    • Shanghai RAAS Blood Products Co., Ltd
    • GC Biopharma Corp.
Product Code: FBI100571

Growth Factors of immunoglobulin Market

The global immunoglobulin market was valued at USD 22.15 billion in 2025 and is projected to grow to USD 24.44 billion in 2026, eventually reaching USD 43.68 billion by 2034, exhibiting a CAGR of 7.53% during the forecast period. North America dominated the market in 2025, holding a 49.39% share, driven by the rising prevalence of immunodeficiency diseases, strong healthcare infrastructure, and innovative product launches.

Immunoglobulins, derived from human plasma, are critical therapies for immunodeficiency disorders, autoimmune conditions, and other chronic immune-mediated diseases. Their growing use as first-line treatments and the ongoing R&D investment by leading pharmaceutical companies such as CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), and Octapharma AG (Switzerland) are key factors driving market expansion. Regulatory support and expedited approvals for new immunoglobulin products further strengthen the market growth trajectory.

Market Trends

A prominent global trend is the shift toward subcutaneous administration (SCIG). SCIG provides multiple advantages over intravenous administration (IVIG), including easier administration, improved safety, and the ability for patients to self-administer at home. This trend supports higher patient adherence and broader adoption. For instance, in June 2023, Grifols, S.A. launched XEMBIFY, a 20% SCIG product in Spain to boost accessibility and growth.

Market Drivers

The rising demand for treatment of immunodeficiency diseases such as Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome, and Multifocal Motor Neuropathy (MMN) drives immunoglobulin market growth. The increasing prevalence of these conditions expands the patient population and, consequently, the demand for immunoglobulin therapies. According to a February 2025 report by the U.S. Pharmacist, approximately 1-2% of the U.S. population is affected by primary immunodeficiency disorders (PIDDs).

Market Restraints

Stringent government regulations act as a significant restraint. Immunoglobulins are plasma-derived and must meet strict safety, potency, and quality standards. Regulatory bodies such as the U.S. FDA monitor plasma collection, processing, and distribution under the Public Health Service (PHS) Act and Federal Food, Drug, and Cosmetic (FD&C) Act. These requirements can limit rapid market expansion and increase production costs.

Market Opportunities

Expanding manufacturing capacity presents a major growth opportunity. Plasma availability and production constraints often create supply chain challenges. Companies are investing in higher-throughput purification systems, expanded fractionation lines, and improved packaging to meet rising demand. In February 2025, Octapharma AG expanded its Vienna manufacturing facilities to increase production of human plasma-based medicines.

Market Challenges

The high cost of immunoglobulin therapies poses a critical challenge. IVIG and SCIG therapies are expensive, with high out-of-pocket costs and variable reimbursement policies. Supply shortages also contribute to higher prices, restricting adoption. For example, a 2024 study on Myasthenia Gravis patients in Norway showed that IVIG treatment resulted in 2.3 times higher direct medical costs in the first year compared to untreated patients.

Market Segmentation

By Product Type:

  • IVIG dominates the market due to hospital use and rapid onset of action for severe neuro-immunology conditions.
  • SCIG is expected to grow at a CAGR of 11.18%, driven by self-administration convenience and patient preference.

By Form:

  • Liquid immunoglobulin dominates in 2025, offering ready-to-use formulations that reduce contamination risk and preparation time.
  • Lyophilized form is projected to grow at a CAGR of 2.97% during the forecast period.

By End User:

  • Hospitals hold the largest share due to established infrastructure, patient monitoring, and reimbursement pathways.
  • Home care is projected to grow at a CAGR of 9.18%, reflecting the rising adoption of SCIG therapies.

Regional Outlook

North America led the market with USD 11.46 billion in 2025, projected to reach USD 12.47 billion in 2026. The U.S. market alone is expected at USD 11.19 billion in 2026.

Europe generated USD 3.63 billion in 2025, reaching USD 3.91 billion in 2026, driven by government support and infrastructure development. Germany and the U.K. markets are estimated at USD 1.24 billion and USD 1.04 billion, respectively, in 2026.

Asia Pacific accounted for USD 3.38 billion in 2025, projected to reach USD 3.71 billion in 2026, with Japan and China leading at USD 1.41 billion and USD 2.12 billion, respectively. India is expected at USD 0.68 billion in 2026.

Latin America and Middle East & Africa are projected to grow moderately, with market sizes of USD 0.45 billion and USD 0.18 billion, respectively, in 2026. The GCC region alone is expected to reach USD 0.30 billion.

Competitive Landscape

The market is highly consolidated with key players including CSL, Takeda, Grifols, Kedrion, Octapharma, ADMA Biologics, Taibang Biologic, LFB Group, Shanghai RAAS Blood Products, and GC Biopharma. Strategic partnerships, new product launches, and regulatory approvals are core strategies driving their market positions. Notable developments include Takeda's Orphan Drug Designation for mezagitamab in June 2025 and Grifols' IND submission for GRF312 in May 2025.

Conclusion

The global immunoglobulin market is poised for strong growth from USD 22.15 billion in 2025 to USD 43.68 billion by 2034, driven by rising immunodeficiency disease prevalence, innovative product launches, and expanding manufacturing capacities. While regulatory restrictions and high therapy costs pose challenges, technological innovations and strategic partnerships continue to propel the market forward.

Segmentation By Product Type, Form, End User, and Region

By Product Type * Intravenous Immunoglobulin (IVIG)

    • Primary Immunodeficiency
    • Secondary Immunodeficiency
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Guillain-Barre Syndrome
    • Immune Thrombocytopenic Purpura
    • Multifocal Motor Neuropathy
    • Others
  • Subcutaneous Immunoglobulin (SCIG)
    • Primary Immunodeficiency
    • Secondary Immunodeficiency
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Others

By Form * Liquid

  • Lyophilized

By End User * Hospitals

  • Clinics
  • Homecare

By Region * North America (By Product Type, Form, End User, and Country)

    • U.S.
    • Canada
  • Europe (By Product Type, Form, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product Type, Form, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product Type, Form, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product Type, Form, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Pipeline Analysis, By Key Players
  • 4.2. Key Industry Developments (Mergers, Acquisitions, etc.)
  • 4.3. New Product Launches, By Key Players
  • 4.4. Overview of Regulatory & Reimbursement Scenario, By Key Countries/Regions
  • 4.5. Prevalence of Major Diseases, By Key Countries/Regions

5. Global Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Intravenous Immunoglobulin (IVIG)
      • 5.1.1.1. Primary Immunodeficiency
      • 5.1.1.2. Secondary Immunodeficiency
      • 5.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 5.1.1.4. Guillain-Barre Syndrome
      • 5.1.1.5. Immune Thrombocytopenic Purpura
      • 5.1.1.6. Multifocal Motor Neuropathy
      • 5.1.1.7. Others
    • 5.1.2. Subcutaneous Immunoglobulin (SCIG)
      • 5.1.2.1. Primary Immunodeficiency
      • 5.1.2.2. Secondary Immunodeficiency
      • 5.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 5.1.2.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Form
    • 5.2.1. Liquid
    • 5.2.2. Lyophilized
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospitals
    • 5.3.2. Clinics
    • 5.3.3. Homecare
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Intravenous Immunoglobulin (IVIG)
      • 6.1.1.1. Primary Immunodeficiency
      • 6.1.1.2. Secondary Immunodeficiency
      • 6.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 6.1.1.4. Guillain-Barre Syndrome
      • 6.1.1.5. Immune Thrombocytopenic Purpura
      • 6.1.1.6. Multifocal Motor Neuropathy
      • 6.1.1.7. Others
    • 6.1.2. Subcutaneous Immunoglobulin (SCIG)
      • 6.1.2.1. Primary Immunodeficiency
      • 6.1.2.2. Secondary Immunodeficiency
      • 6.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 6.1.2.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Form
    • 6.2.1. Liquid
    • 6.2.2. Lyophilized
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospitals
    • 6.3.2. Clinics
    • 6.3.3. Homecare
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Intravenous Immunoglobulin (IVIG)
      • 7.1.1.1. Primary Immunodeficiency
      • 7.1.1.2. Secondary Immunodeficiency
      • 7.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 7.1.1.4. Guillain-Barre Syndrome
      • 7.1.1.5. Immune Thrombocytopenic Purpura
      • 7.1.1.6. Multifocal Motor Neuropathy
      • 7.1.1.7. Others
    • 7.1.2. Subcutaneous Immunoglobulin (SCIG)
      • 7.1.2.1. Primary Immunodeficiency
      • 7.1.2.2. Secondary Immunodeficiency
      • 7.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 7.1.2.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Form
    • 7.2.1. Liquid
    • 7.2.2. Lyophilized
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Homecare
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Intravenous Immunoglobulin (IVIG)
      • 8.1.1.1. Primary Immunodeficiency
      • 8.1.1.2. Secondary Immunodeficiency
      • 8.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 8.1.1.4. Guillain-Barre Syndrome
      • 8.1.1.5. Immune Thrombocytopenic Purpura
      • 8.1.1.6. Multifocal Motor Neuropathy
      • 8.1.1.7. Others
    • 8.1.2. Subcutaneous Immunoglobulin (SCIG)
      • 8.1.2.1. Primary Immunodeficiency
      • 8.1.2.2. Secondary Immunodeficiency
      • 8.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 8.1.2.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Form
    • 8.2.1. Liquid
    • 8.2.2. Lyophilized
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospitals
    • 8.3.2. Clinics
    • 8.3.3. Homecare
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Southeast Asia
    • 8.4.5. Australia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Intravenous Immunoglobulin (IVIG)
      • 9.1.1.1. Primary Immunodeficiency
      • 9.1.1.2. Secondary Immunodeficiency
      • 9.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 9.1.1.4. Guillain-Barre Syndrome
      • 9.1.1.5. Immune Thrombocytopenic Purpura
      • 9.1.1.6. Multifocal Motor Neuropathy
      • 9.1.1.7. Others
    • 9.1.2. Subcutaneous Immunoglobulin (SCIG)
      • 9.1.2.1. Primary Immunodeficiency
      • 9.1.2.2. Secondary Immunodeficiency
      • 9.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 9.1.2.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Form
    • 9.2.1. Liquid
    • 9.2.2. Lyophilized
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospitals
    • 9.3.2. Clinics
    • 9.3.3. Homecare
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. Intravenous Immunoglobulin (IVIG)
      • 10.1.1.1. Primary Immunodeficiency
      • 10.1.1.2. Secondary Immunodeficiency
      • 10.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 10.1.1.4. Guillain-Barre Syndrome
      • 10.1.1.5. Immune Thrombocytopenic Purpura
      • 10.1.1.6. Multifocal Motor Neuropathy
      • 10.1.1.7. Others
    • 10.1.2. Subcutaneous Immunoglobulin (SCIG)
      • 10.1.2.1. Primary Immunodeficiency
      • 10.1.2.2. Secondary Immunodeficiency
      • 10.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 10.1.2.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Form
    • 10.2.1. Liquid
    • 10.2.2. Lyophilized
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Hospitals
    • 10.3.2. Clinics
    • 10.3.3. Homecare
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. CSL
    • 11.2.2. Takeda Pharmaceutical Company Limited
    • 11.2.3. Grifols, S.A.
    • 11.2.4. Kedrion S.p.A
    • 11.2.5. Octapharma AG
    • 11.2.6. ADMA Biologics, Inc.
    • 11.2.7. Taibang Biologic Group (China Biologic Products Holdings, Inc.)
    • 11.2.8. LFB Group
    • 11.2.9. Shanghai RAAS Blood Products Co., Ltd
    • 11.2.10. GC Biopharma Corp.

List of Tables

  • Table 1: Global Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 2: Global Immunoglobulin Market Revenue (USD billion) Forecast, by Intravenous Immunoglobulin (IVIG), 2021-2034
  • Table 3: Global Immunoglobulin Market Revenue (USD billion) Forecast, by Subcutaneous Immunoglobulin (SCIG), 2021-2034
  • Table 4: Global Immunoglobulin Market Revenue (USD billion) Forecast, by Form, 2021-2034
  • Table 5: Global Immunoglobulin Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 6: Global Immunoglobulin Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type 2021-2034
  • Table 8: North America Immunoglobulin Market Revenue (USD billion) Forecast, by Intravenous Immunoglobulin (IVIG), 2021-2034
  • Table 9: North America Immunoglobulin Market Revenue (USD billion) Forecast, by Subcutaneous Immunoglobulin (SCIG), 2021-2034
  • Table 10: North America Immunoglobulin Market Revenue (USD billion) Forecast, by Form, 2021-2034
  • Table 11: North America Immunoglobulin Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 12: North America Immunoglobulin Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 13: Europe Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type 2021-2034
  • Table 14: Europe Immunoglobulin Market Revenue (USD billion) Forecast, by Intravenous Immunoglobulin (IVIG), 2021-2034
  • Table 15: Europe Immunoglobulin Market Revenue (USD billion) Forecast, by Subcutaneous Immunoglobulin (SCIG), 2021-2034
  • Table 16: Europe Immunoglobulin Market Revenue (USD billion) Forecast, by Form, 2021-2034
  • Table 17: Europe Immunoglobulin Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 18: Europe Immunoglobulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type 2021-2034
  • Table 20: Asia Pacific Immunoglobulin Market Revenue (USD billion) Forecast, by Intravenous Immunoglobulin (IVIG), 2021-2034
  • Table 21: Asia Pacific Immunoglobulin Market Revenue (USD billion) Forecast, by Subcutaneous Immunoglobulin (SCIG), 2021-2034
  • Table 22: Asia Pacific Immunoglobulin Market Revenue (USD billion) Forecast, by Form, 2021-2034
  • Table 23: Asia Pacific Immunoglobulin Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 24: Asia Pacific Immunoglobulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 25: Latin America Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type 2021-2034
  • Table 26: Latin America Immunoglobulin Market Revenue (USD billion) Forecast, by Intravenous Immunoglobulin (IVIG), 2021-2034
  • Table 27: Latin America Immunoglobulin Market Revenue (USD billion) Forecast, by Subcutaneous Immunoglobulin (SCIG), 2021-2034
  • Table 28: Latin America Immunoglobulin Market Revenue (USD billion) Forecast, by Form, 2021-2034
  • Table 29: Latin America Immunoglobulin Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 30: Latin America Immunoglobulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type 2021-2034
  • Table 32: Middle East & Africa Immunoglobulin Market Revenue (USD billion) Forecast, by Intravenous Immunoglobulin (IVIG), 2021-2034
  • Table 33: Middle East & Africa Immunoglobulin Market Revenue (USD billion) Forecast, by Subcutaneous Immunoglobulin (SCIG), 2021-2034
  • Table 34: Middle East & Africa Immunoglobulin Market Revenue (USD billion) Forecast, by Form, 2021-2034
  • Table 35: Middle East & Africa Immunoglobulin Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 36: Middle East & Africa Immunoglobulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Immunoglobulin Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Immunoglobulin Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 3: Global Immunoglobulin Market Value Share (%), by Form, 2025 & 2034
  • Figure 4: Global Immunoglobulin Market Value Share (%), by End User, 2025 & 2034
  • Figure 5: Global Immunoglobulin Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Immunoglobulin Market Value (USD billion), by Product Type 2025 & 2034
  • Figure 7: North America Immunoglobulin Market Value Share (%), by Product Type 2025
  • Figure 8: North America Immunoglobulin Market Value (USD billion), by Form, 2025 & 2034
  • Figure 9: North America Immunoglobulin Market Value Share (%), by Form, 2025
  • Figure 10: North America Immunoglobulin Market Value (USD billion), by End User, 2025 & 2034
  • Figure 11: North America Immunoglobulin Market Value Share (%), by End User, 2025
  • Figure 12: North America Immunoglobulin Market Value (USD billion), by Country, 2025 & 2034
  • Figure 13: North America Immunoglobulin Market Value Share (%), by Country, 2025
  • Figure 14: Europe Immunoglobulin Market Value (USD billion), by Product Type 2025 & 2034
  • Figure 15: Europe Immunoglobulin Market Value Share (%), by Product Type 2025
  • Figure 16: Europe Immunoglobulin Market Value (USD billion), by Form, 2025 & 2034
  • Figure 17: Europe Immunoglobulin Market Value Share (%), by Form, 2025
  • Figure 18: Europe Immunoglobulin Market Value (USD billion), by End User, 2025 & 2034
  • Figure 19: Europe Immunoglobulin Market Value Share (%), by End User, 2025
  • Figure 20: Europe Immunoglobulin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Immunoglobulin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Immunoglobulin Market Value (USD billion), by Product Type 2025 & 2034
  • Figure 23: Asia Pacific Immunoglobulin Market Value Share (%), by Product Type 2025
  • Figure 24: Asia Pacific Immunoglobulin Market Value (USD billion), by Form, 2025 & 2034
  • Figure 25: Asia Pacific Immunoglobulin Market Value Share (%), by Form, 2025
  • Figure 26: Asia Pacific Immunoglobulin Market Value (USD billion), by End User, 2025 & 2034
  • Figure 27: Asia Pacific Immunoglobulin Market Value Share (%), by End User, 2025
  • Figure 28: Asia Pacific Immunoglobulin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Immunoglobulin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 30: Latin America Immunoglobulin Market Value (USD billion), by Product Type 2025 & 2034
  • Figure 31: Latin America Immunoglobulin Market Value Share (%), by Product Type 2025
  • Figure 32: Latin America Immunoglobulin Market Value (USD billion), by Form, 2025 & 2034
  • Figure 33: Latin America Immunoglobulin Market Value Share (%), by Form, 2025
  • Figure 34: Latin America Immunoglobulin Market Value (USD billion), by End User, 2025 & 2034
  • Figure 35: Latin America Immunoglobulin Market Value Share (%), by End User, 2025
  • Figure 36: Latin America Immunoglobulin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Immunoglobulin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Immunoglobulin Market Value (USD billion), by Product Type 2025 & 2034
  • Figure 39: Middle East & Africa Immunoglobulin Market Value Share (%), by Product Type 2025
  • Figure 40: Middle East & Africa Immunoglobulin Market Value (USD billion), by Form, 2025 & 2034
  • Figure 41: Middle East & Africa Immunoglobulin Market Value Share (%), by Form, 2025
  • Figure 42: Middle East & Africa Immunoglobulin Market Value (USD billion), by End User, 2025 & 2034
  • Figure 43: Middle East & Africa Immunoglobulin Market Value Share (%), by End User, 2025
  • Figure 44: Middle East & Africa Immunoglobulin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Immunoglobulin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 46: Global Immunoglobulin Market Share (%), by Company, 2025